89Bio

89Bio company information, Employees & Contact Information

Explore related pages

Related company profiles:

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Recent Phase 1b/2a data show BIO89-100 demonstrated a favorable safety and tolerability profile and robust reductions in liver fat and key lipid markers when dosed weekly or once every two weeks in patients with NASH. BIO89-100 is currently in a Phase 2 trial for the treatment of SHTG. 89bio is headquartered in San Francisco with operations in Herzliya, Israel. Our culture is best described by our values: • Always putting the patient first • Operating with the highest integrity and ethical standards at all times • Being authentic in all our transactions • Acting as a team – collaborating, respecting and caring for one another • Being entrepreneurial and passionate in our tasks • Being scientific and rational in our thought process and decision-making

Company Details

Employees
138
Founded
-
Address
San Francisco, Ca, Us
Email
in****@****bio.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
89bio.com
HQ
San Francisco, CA
Looking for a particular 89Bio employee's phone or email?

89bio Questions

News

89bio to Participate in Upcoming Investor Conferences - Yahoo Finance

89bio to Participate in Upcoming Investor Conferences Yahoo Finance

89bio to be Acquired by Roche for Up to $20.50 per Share, Totaling $3.5 Billion in Transaction Value - Quiver Quantitative

89bio to be Acquired by Roche for Up to $20.50 per Share, Totaling $3.5 Billion in Transaction Value Quiver Quantitative

Roche commences tender offer for all shares of 89bio, Inc. - GlobeNewswire

Roche commences tender offer for all shares of 89bio, Inc. GlobeNewswire

Biotech 89bio Grants 64,750 Stock Options to New Hires with 4-Year Vesting Schedule - Stock Titan

Biotech 89bio Grants 64,750 Stock Options to New Hires with 4-Year Vesting Schedule Stock Titan

$3.5 Billion Biotech Deal: Roche Acquires 89bio for Breakthrough MASH Treatment Pegozafermin - Stock Titan

$3.5 Billion Biotech Deal: Roche Acquires 89bio for Breakthrough MASH Treatment Pegozafermin Stock Titan

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Yahoo Finance

Roche to acquire liver drug developer 89bio for up to $3.5 billion - Reuters

Roche to acquire liver drug developer 89bio for up to $3.5 billion Reuters

After courting 14 pharmas, 89bio was left between a Roche and hard place in buyout talks - Fierce Biotech

After courting 14 pharmas, 89bio was left between a Roche and hard place in buyout talks Fierce Biotech

89bio, Inc. Prices Upsized Public Offering of Common Stock and Pre-funded Warrants Expected to Raise Approximately $250 Million - Quiver Quantitative

89bio, Inc. Prices Upsized Public Offering of Common Stock and Pre-funded Warrants Expected to Raise Approximately $250 Million Quiver Quantitative

$20.50 Per Share Deal: Roche Makes Move to Acquire 89bio in Major Biotech Tender Offer - Stock Titan

$20.50 Per Share Deal: Roche Makes Move to Acquire 89bio in Major Biotech Tender Offer Stock Titan

Roche to buy 89bio in deal worth up to $3.5B, picking up MASH drug - statnews.com

Roche to buy 89bio in deal worth up to $3.5B, picking up MASH drug statnews.com

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH? - Endpoints News

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH? Endpoints News

89bio Awards Major Stock Options Package: 267,000 Shares to 3 New Hires in Liver Disease Research Push - Stock Titan

89bio Awards Major Stock Options Package: 267,000 Shares to 3 New Hires in Liver Disease Research Push Stock Titan

Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH - Yahoo Finance

Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH Yahoo Finance

$3.5B Potential Deal: Roche Acquires 89bio's Breakthrough MASH Treatment in Major Metabolic Disease Push - Stock Titan

$3.5B Potential Deal: Roche Acquires 89bio's Breakthrough MASH Treatment in Major Metabolic Disease Push Stock Titan

RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline - Yahoo Finance

RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline Yahoo Finance

Liver Disease Biotech 89bio Lines Up Triple Conference Presence: Citi, Cantor, and H.C. Wainwright - Stock Titan

Liver Disease Biotech 89bio Lines Up Triple Conference Presence: Citi, Cantor, and H.C. Wainwright Stock Titan

Roche dives into MASH with $2.4B deal for 89bio - BioPharma Dive

Roche dives into MASH with $2.4B deal for 89bio BioPharma Dive

Roche Makes Major MASH Move With $3.5B 89bio Buy - BioSpace

Roche Makes Major MASH Move With $3.5B 89bio Buy BioSpace

Roche becomes MASH player via $3.5B deal for 89bio and its phase 3 drug - Fierce Biotech

Roche becomes MASH player via $3.5B deal for 89bio and its phase 3 drug Fierce Biotech

Roche to Buy Biopharmceutical Firm 89bio in $3.5 Billion Deal - Bloomberg.com

Roche to Buy Biopharmceutical Firm 89bio in $3.5 Billion Deal Bloomberg.com

How Akero’s MASH Success Drove Roche’s $3.5B Takeout of 89bio - BioSpace

How Akero’s MASH Success Drove Roche’s $3.5B Takeout of 89bio BioSpace

89bio: Pegozafermin MASH Drug Advancement Nets Roche Acquisition (NASDAQ:ETNB) - Seeking Alpha

89bio: Pegozafermin MASH Drug Advancement Nets Roche Acquisition (NASDAQ:ETNB) Seeking Alpha

Pegozafermin improves fibrosis, shows promise as ‘mainstay treatment’ for NASH - Healio

Pegozafermin improves fibrosis, shows promise as ‘mainstay treatment’ for NASH Healio

Roche Expands Cardiometabolic Pipeline With 89bio Acquisition (OTCMKTS:RHHBY) - Seeking Alpha

Roche Expands Cardiometabolic Pipeline With 89bio Acquisition (OTCMKTS:RHHBY) Seeking Alpha

89bio: Promising As Pegozafermin Nears Phase 3 Readout (NASDAQ:ETNB) - Seeking Alpha

89bio: Promising As Pegozafermin Nears Phase 3 Readout (NASDAQ:ETNB) Seeking Alpha

Roche acquires 89bio for US$3.5bn - European Biotechnology Magazine

Roche acquires 89bio for US$3.5bn European Biotechnology Magazine

Roche punts up to $3.5B to acquire 89bio - The Pharma Letter

Roche punts up to $3.5B to acquire 89bio The Pharma Letter

89bio: A Buy With Strong Market Opportunity In MASH And SHTG - Seeking Alpha

89bio: A Buy With Strong Market Opportunity In MASH And SHTG Seeking Alpha

Switzerland’s Roche strikes $3.5bn deal to buy US drugmaker 89bio - Financial Times

Switzerland’s Roche strikes $3.5bn deal to buy US drugmaker 89bio Financial Times

Why 89bio Stock Lagged the Market Today - The Motley Fool

Why 89bio Stock Lagged the Market Today The Motley Fool

Roche deal to buy 89bio boosts MASH space (ETNB:NASDAQ) - Seeking Alpha

Roche deal to buy 89bio boosts MASH space (ETNB:NASDAQ) Seeking Alpha

Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push - Benzinga

Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push Benzinga

Pegozafermin Shows Sustained Benefit for NASH in Phase 2b Extension Study - HCPLive

Pegozafermin Shows Sustained Benefit for NASH in Phase 2b Extension Study HCPLive

89bio’s Pegozafermin Is Now Gaining Momentum (NASDAQ:ETNB) - Seeking Alpha

89bio’s Pegozafermin Is Now Gaining Momentum (NASDAQ:ETNB) Seeking Alpha

Pegozafermin Enters Phase 3 Clinical Trial Program for MASH, Fibrosis - HCPLive

Pegozafermin Enters Phase 3 Clinical Trial Program for MASH, Fibrosis HCPLive

MASH dash speeds up as Roche acquires 89bio for up to $3.5B - BioWorld MedTech

MASH dash speeds up as Roche acquires 89bio for up to $3.5B BioWorld MedTech

89bio Stock Skyrockets After Roche’s $3.5B Buyout Offer: Retail Bullish, But A Wall Street Analyst Is Cautious - Stocktwits

89bio Stock Skyrockets After Roche’s $3.5B Buyout Offer: Retail Bullish, But A Wall Street Analyst Is Cautious Stocktwits

89bio (ETNB) Q2 R&D Jumps 131% - The Motley Fool

89bio (ETNB) Q2 R&D Jumps 131% The Motley Fool

89bio lines up China CDMO to build API plant for commercial production of MASH candidate - Fierce Pharma

89bio lines up China CDMO to build API plant for commercial production of MASH candidate Fierce Pharma

Pegazofermin Enters Phase 3 ENLIGHTEN Clinical Trial Program for MASH - Patient Care Online

Pegazofermin Enters Phase 3 ENLIGHTEN Clinical Trial Program for MASH Patient Care Online

89bio, Inc. Announces Upsized Pricing of $94.5 - GlobeNewswire

89bio, Inc. Announces Upsized Pricing of $94.5 GlobeNewswire

ENLIVEN: Pegozafermin Could Reduce, Improve Fibrosis in NASH - HCPLive

ENLIVEN: Pegozafermin Could Reduce, Improve Fibrosis in NASH HCPLive

89bio Announces Closing of its Upsized $94.5 Million Public - GlobeNewswire

89bio Announces Closing of its Upsized $94.5 Million Public GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) By Investing.com - Investing.com South Africa

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) By Investing.com Investing.com South Africa

89bio Appoints Hank Mansbach, M.D., as Chief Medical Officer - PR Newswire

89bio Appoints Hank Mansbach, M.D., as Chief Medical Officer PR Newswire

Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies - GlobeNewswire

Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies GlobeNewswire

ETNB Stock Price and Chart — NASDAQ:ETNB - TradingView

ETNB Stock Price and Chart — NASDAQ:ETNB TradingView

Top 89Bio Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant